4 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With MigraineAcute Treatment of MigraineRecruitingPhase 42026-09-25NCT07609914
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic MigraineHeadache, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and SymptomsActive, not recruitingPhase 32026-02-27NCT04616326
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic MigraineHeadache, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and SymptomsActive, not recruitingPhase 32026-01-26NCT03432286
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathyActive, not recruitingPhase 32026-01-21NCT05026866